VRTX Stock Price Today (September 2026) — Vertex Pharmaceuticals Incorporated Analysis & Key Metrics 2026-09-03
Vertex Pharmaceuticals Incorporated (VRTX) is trading at $557.96, up 0.22% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $563.12 (0.9% upside).
- Volatility remains elevated (22.29% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (12.50% YoY) alongside significant competitive pressures.
VRTX Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Vertex Pharmaceuticals Incorporated - Historical Price & Volume
Market Cap
Enterprise Value: $131.42B
P/E Ratio
Forward P/E: 24.75
Revenue Growth
Year over Year
Analyst Target
+0.9% upside potential
Key Investor Questions About VRTX
What investors need to know before buying
Based on current market data, VRTX presents a overbought technical setup with caution warranted fundamentals.
- Technicals say: Overbought (RSI 70.03)
- Fundamentals say: Caution warranted (high leverage concerns)
VRTX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for VRTX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.98B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, VRTX stock traded between $374.17 and $555.69—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 22.29% annualized volatility and β=0.50, the stock exhibits low sensitivity to market moves—making VRTX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
We'll know a little more about the company's prospects by the end of the year.
How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?
Vertex Pharmaceuticals has underperformed the Biotech industry over the past year, but analysts are moderately optimistic about the stock’s prospects.
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks
Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today’s valuation, while any...
Goldman Sachs refreshes conviction lists on both sides of the Atlantic
Investing.com -- Goldman Sachs updated its U.S. and European conviction lists for September, adding several new names as it refreshed its highest-conviction ideas heading into the autumn.
Vertex Pharmaceuticals (VRTX) Could Be 3% Undervalued If Its Pipeline Growth Holds
How Vertex Pharmaceuticals Stock Has Been Trading Recently Vertex Pharmaceuticals (VRTX) has drawn fresh investor attention as its share price reached $544.52 at the last close on 1 September 2026. Recent returns show mixed short term moves, with stronger performance over the past 3 months and over the past year. Over the past year, Vertex Pharmaceuticals has combined a strong 90 day share price return of 28.10% with a 1 year total shareholder return of 39.26%. This suggests that recent price...
Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.
1 S&P 500 Stock with Exciting Potential and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
Explore More Analysis for VRTX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) is currently trading at $557.96. The RSI (14-day) is at 70.0, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $563.12 implies 0.9% upside from current levels. Volatility is moderate at 22.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Vertex Pharmaceuticals Incorporated (VRTX): The trailing P/E ratio is 32.33, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 24.75, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.90, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 6.98. Price-to-Sales is 11.24. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering VRTX, the consensus price target is $563.12. This represents a 0.9% upside from the current price of $557.96. The range spans from a low target of $350.00 to a high target of $672.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Vertex Pharmaceuticals Incorporated (VRTX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Vertex Pharmaceuticals Incorporated (VRTX) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Vertex Pharmaceuticals Incorporated's (VRTX) current debt and financial health profile: Total debt stands at $1.98B. The debt-to-equity ratio is 9.77, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.19, indicating strong short-term liquidity. The quick ratio is 2.54. The company holds $7.85B in cash and equivalents. Free cash flow is positive at $2.63B, providing a cushion for debt servicing and shareholder returns.